Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for postoperative depressive symptoms in gynecologic surgery patients
ChiCTR2600131415Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wannan Medical College
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of esketamine in major depressive disorder (MDD) (2 arms), sponsored by The First Affiliated Hospital of Wannan Medical College. Primary endpoint: Postoperative depression score. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2600131415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131415.